Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

Article Authors: Peter Stein, Jolene K Berg, Linda Morrow, David Polidori, Eunice Artis, Sarah Rusch, Nicole Vaccaro, Damayanthi Devineni

no alt text set

Abstract

Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved for treating patients with type 2 diabetes. This study evaluated renal and non-renal effects of canagliflozin on postprandial plasma glucose (PG) excursion in patients with type 2 diabetes inadequately controlled with metformin.

no